Article
Pharmacology & Pharmacy
Fang Wang, Xiaofei Li, Yanting Shi, He Zhou, Gang Yang, Ruixia Li, Tong Wu, Jie Liang
Summary: This study found that the ADA biosimilar HS016 had good efficacy and safety in Chinese IBD patients. The majority of Crohn's disease and ulcerative colitis patients achieved clinical response and remission after treatment with HS016.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Diego Casas-Deza, Luis Javier Lamuela-Calvo, Fernando Gomollon, Jose Miguel Arbones-Mainar, Berta Caballol, Javier P. Gisbert, Montserrat Rivero, Eugenia Sanchez-Rodriguez, Lara Arias Garcia, Ana Gutierrez Casbas, Olga Merino, Lucia Marquez, Viviana Laredo, Maria Dolores Martin-Arranz, Pilar Lopez Serrano, Sabino Riestra Menendez, Carlos Gonzalez-Munoza, Luisa de Castro Parga, Marta Calvo Moya, Esteban Fuentes-Valenzuela, Maria Esteve, Marisa Iborra, Miguel Dura Gil, Manuel Barreiro-De Acosta, Rufo Humberto Lorente-Poyatos, Noemi Mancenido, Margalida Calafat, Iago Rodriguez-Lago, Jordi Guardiola Capo, Maria Antonia Payeras, Victor Jair Morales Alvarado, Carlos Tardillo, Luis Bujanda, Jose Fernando Munoz-Nunez, Yolanda Ber Nieto, Fernando Bermejo, Pedro Almela, Merce Navarro-Llavat, Pilar Martinez Montiel, Cristina Rodriguez Gutierrez, Manuel Van Domselaar, Eva Sese, Teresa Martinez Perez, Elena Ricart, Maria Chaparro, Maria Jose Garcia, Antonio Lopez-Sanroman, Beatriz Sicilia, Beatriz Orts, Alicia Lopez-Garcia, Eduardo Martin-Larraz, Jose Lazaro Perez-Calle, Ruth de Francisco, Esther Garcia-Planella, Eugeni Domenech, Santiago Garcia-Loper
Summary: Ustekinumab shows similar effectiveness in elderly patients with CD as it does in non-elderly patients. The safety profile is also similar, except for a higher rate of de novo neoplasms in elderly patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Nikolas Plevris, James Fulforth, Spyros Siakavellas, Andrew Robertson, Rebecca Hall, Amy Tyler, Philip W. Jenkinson, Iona Campbell, Cher Shiong Chuah, Claire Kane, Jennifer Veryan, Wai Liam Lam, Jayne Saunders, Christopher Kelly, Daniel Gaya, Hasnain Jafferbhoy, Jonathan C. Macdonald, John Paul Seenan, Craig Mowat, Graham Naismith, Lindsay F. Potts, Diarmid Ian Sutherland, David Watts, Ian Arnott, Gillian Bain, Gareth Jones, Charlie W. Lees
Summary: The study aimed to evaluate the real-world effectiveness and safety of ustekinumab for treating Crohn's disease in patients in Scotland. Results showed that ustekinumab is a safe and effective treatment for complex Crohn's disease, with good rates of clinical remission, mucosal healing, and deep remission observed in the study.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Maria Chaparro, Iria Baston-Rey, Estela Fernandez-Salgado, Javier Gonzalez Garcia, Laura Ramos, Maria Teresa Diz-Lois Palomares, Federico Arguelles-Arias, Eva Iglesias Flores, Mercedes Cabello, Saioa Rubio Iturria, Andrea Nunez Ortiz, Mara Charro, Daniel Ginard, Carmen Duenas Sadornil, Olga Merino Ochoa, David Busquets, Eduardo Iyo, Ana Gutierrez Casbas, Patricia Ramirez de la Piscina, Marta Maia Bosca-Watts, Maite Arroyo, Maria Jose Garcia, Esther Hinojosa, Jordi Gordillo, Pilar Martinez Montiel, Benito Velayos Jimenez, Cristina Quilez Ivorra, Juan Maria Vazquez Moron, Jose Maria Huguet, Yago Gonzalez-Lama, Ana Isabel Munagorri Santos, Victor Manuel Amo, Maria Dolores Martin-Arranz, Fernando Bermejo, Jesus Martinez Cadilla, Cristina Rubin de Celix, Paola Fradejas Salazar, Antonio Lopez San Roman, Nuria Jimenez, Santiago Garcia Lopez, Anna Figuerola, Itxaso Jimenez, Francisco Jose Martinez Cerezo, Carlos Taxonera, Pilar Varela, Ruth de Francisco, David Monfort, Gema Molina Arriero, Alejandro Hernandez Camba, Francisco Javier Garcia-Alonso, Manuel Van Domselaar, Ramon Pajares Villarroya, Alejandro Nunez, Francisco Rodriguez Moranta, Ignacio Marin-Jimenez, Virginia Robles Alonso, Maria del Mar Martin Rodriguez, Patricia Camo-Monterde, Ivan Garcia Tercero, Mercedes Navarro Llavat, Lara Arias Garcia, Daniel Hervias Cruz, Sara Sulleiro, Cynthia Novella, Eugenia Vispo, Manuel Barreiro-de Acosta, Javier P. Gisbert
Summary: This large retrospective study demonstrates the effectiveness and safety of ustekinumab as a short- and long-term treatment option for patients with Crohn's disease in real-world clinical practice, including those with refractory disease.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Rajat Garg, Manik Aggarwal, Robert Butler, Jean Paul Achkar, Bret Lashner, Jessica Philpott, Benjamin Cohen, Taha Qazi, Florian Rieder, Miguel Regueiro, Benjamin Click
Summary: UST is safe and effective in elderly CD patients, with similar outcomes as nonelderly patients. Age is not associated with clinical outcomes, while differences exist between elderly and nonelderly patients in Crohn's disease activity and prior biologic use. Real-world data in this IBD population can help inform biologic positioning.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Maria Chaparro, Ana Garre, Marisa Iborra, Monica Sierra-Ausin, Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Luisa de Castro, Maia Bosca-Watts, Maria Jose Casanova, Alicia Lopez-Garcia, Rufo Lorente, Cristina Rodriguez, Ana Y. Carbajo, Maria Teresa Arroyo, Ana Gutierrez, Joaquin Hinojosa, Teresa Martinez-Perez, Albert Villoria, Fernando Bermejo, David Busquets, Blau Camps, Fiorella Canete, Noemi Mancenido, David Monfort, Merce Navarro-Llavat, Jose Lazaro Perez-Calle, Laura Ramos, Montserrat Rivero, Teresa Angueira, Patricia Camo Monterde, Daniel Carpio, Irene Garcia-de-la-Filia, Carlos Gonzalez-Munoza, Luis Hernandez, Jose M. Huguet, Victor J. Morales, Beatriz Sicilia, Pablo Vega, Isabel Vera, Yamile Zabana, Pilar Nos, Patricia Suarez Alvarez, Cristina Calvino-Suarez, Elena Ricart, Vicent Hernandez, Miguel Minguez, Lucia Marquez, Daniel Hervias Cruz, Saioa Rubio Iturria, Jesus Barrio, Carla Gargallo-Puyuelo, Ruben Frances, Esther Hinojosa, Maria del Moral, Xavier Calvet, Alicia Algaba, Xavier Aldeguer, Jordi Guardiola, Miriam Manosa, Ramon Pajares, Marta Piqueras, Orlando Garcia-Bosch, Pilar Lopez Serrano, Beatriz Castro, Alfredo J. Lucendo, Miguel Montoro, Elena Castro Ortiz, Francisco Mesonero, Esther Garcia-Planella, David A. Fuentes, Inmaculada Bort, Pedro Delgado-Guillena, Lara Arias, Agueda Iglesias, Marta Calvo, Maria Esteve, Eugeni Domenech, Javier P. Gisbert
Summary: Ustekinumab has shown durability and effectiveness in the treatment of ulcerative colitis, even in real life situations. Higher levels of serum C-reactive protein were associated with a lower probability of achieving remission. In the short term, 53% of patients showed a positive response to the treatment.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Carlos Taxonera, David Olivares, Olga N. N. Lopez-Garcia, Cristina Alba
Summary: This study provides evidence on the real-world outcomes of ustekinumab for ulcerative colitis (UC) patients. The meta-analysis confirms the effectiveness of ustekinumab in achieving clinical remission and response in a highly treatment-refractory population of UC patients. The safety profile of ustekinumab is also demonstrated with low rates of adverse events and serious infections.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Pharmacology & Pharmacy
Qiongwen Zhang, Ping He, Tinglun Tian, Xi Yan, Juan Huang, Zhang Zhang, Hong Zheng, Xiaorong Zhong, Ting Luo
Summary: This study evaluates the real-world outcomes of pyrotinib treatment in patients with HER2-positive metastatic breast cancer. The results show that pyrotinib treatment achieved complete response, partial response, and stable disease in 8.0%, 58.4%, and 15.0% of patients, respectively, while 17.7% of patients had progressive disease. The median progression-free survival was 14.1 months. In patients with brain metastases, the median progression-free survival and overall survival were 15.2 and 19.8 months, respectively. Additionally, pyrotinib demonstrated similar efficacy in different subtypes of HER2-positive metastatic breast cancer patients.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Qian Cao, Chunxiao Chen, Xiang Gao, Yan Chen, Naizhong Hu, Jie Liang, Kaichun Wu
Summary: Research shows that ustekinumab is more effective in treating Crohn's disease than anti-tumor necrosis factor treatment for patients who did not respond to previous treatment. The remission rates of ustekinumab are superior to those in the UNITI-1 study.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Amanda M. Johnson, Maria Barsky, Waseem Ahmed, Samantha Zullow, Jonathan Galati, Vipul Jairath, Neeraj Narula, Farhad Peerani, Benjamin H. Click, Elliot S. Coburn, ThucNhi Tran Dang, Stephanie Gold, Manasi Agrawal, Rajat Garg, Manik Aggarwal, Danah Mohammad, Brendan Halloran, Gursimran S. Kochhar, Hannah Todorowski, Nabeeha Mohy Ud Din, James Izanec, Amanda Teeple, Chris Gasink, Erik Muser, Zhijie Ding, Arun Swaminath, Komal Lakhani, Dan Hogan, Samit Datta, Ryan C. Ungaro, Brigid S. Boland, Matthew Bohm, Monika Fischer, Sashidhar Sagi, Anita Afzali, Thomas Ullman, Garrett Lawlor, Daniel C. Baumgart, Shannon Chang, David Hudesman, Dana Lukin, Ellen J. Scherl, Jean-Frederic Colombel, Bruce E. Sands, Corey A. Siegel, Miguel Regueiro, William J. Sandborn, David Bruining, Sunanda Kane, Edward V. Loftus, Parambir S. Dulai
Summary: This study evaluated the real-world effectiveness and safety of ustekinumab in patients with Crohn's disease. The results demonstrated that ustekinumab is a safe and effective treatment option for Crohn's disease, especially for biologic-naive patients.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Urology & Nephrology
Meng Tan, Jing Xu, Ying Tan, Zhen Qu, Feng Yu, Minghui Zhao
Summary: This study described the disease activity, clinical outcome, and patterns of care for lupus nephritis patients receiving belimumab in a real-world setting in China. The results showed that belimumab improved clinical response and reduced the use of glucocorticosteroids.
Article
Biochemistry & Molecular Biology
Seung-Won Jung, Sung Ha Lim, Jae Joon Jeon, Yeon-Woo Heo, Mi Soo Choi, Seung-Phil Hong
Summary: This study compared the efficacy, safety, and drug survival of three commonly used psoriasis biologics and identified factors affecting drug survival. Guselkumab showed superior long-term response and complete remission compared to other biologics, while ustekinumab had lower efficacy. All three biologics had similar safety profiles, but had different side effects.
Article
Pharmacology & Pharmacy
Zhuangzhuang Zheng, Zijing Liu, Haifeng Zhang, Xiao Guo, Xiaojing Jia, Jianfeng Wang, Lingbin Meng, Ying Xin, Xin Jiang
Summary: This study retrospectively analyzed the efficacy and safety of apatinib mesylate in the treatment of advanced hepatocellular carcinoma (HCC). The results showed that apatinib mesylate is an effective treatment for advanced HCC, and its adverse reactions are relatively mild.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Joel R. Rosh, Dan Turner, Anne Griffiths, Stanley A. Cohen, Douglas Jacobstein, Omoniyi J. Adedokun, Lakshmi Padgett, Natalie A. Terry, Christopher O'Brien, Jeffrey S. Hyams
Summary: The study evaluated the pharmacokinetics, safety, and efficacy of ustekinumab in children with moderately to severely active Crohn's disease. It was found that serum ustekinumab concentrations were lower in patients <40 kg compared to those >= 40 kg. Some patients experienced adverse events during treatment, indicating a need for different dosing regimens.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Pharmacology & Pharmacy
A. Tursi, G. Mocci, A. Cuomo, L. Allegretta, G. Aragona, R. Colucci, N. Della Valle, A. Ferronato, G. Forti, F. Gaiani, M. G. Graziani, R. Lorenzetti, F. Luzza, P. Paese, A. Penna, R. Pica, S. Piergallini, G. Pranzo, S. Rodino, A. Scarcelli, C. Zampaletta, C. Cicerone, A. Cocco, G. De'Angelis, L. Donnarumma, M. Franceschi, S. Gallina, G. Grasso, T. Larussa, I Luppino, R. Faggiani, L. Fanigliulo, C. Pagnini, P. Perazzo, R. Sacco, L. Sebkova, S. Scorza, M. Serio, A. De Monti, M. Picchio, W. Elisei, G. Maconi
Summary: UST appears to be highly effective and safe in CD patients who have not responded to other biologic treatments, particularly when used as a second-line therapy.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)